Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Hyperprolactinemia) articles in PubMed
6,429 results
  • Antipsychotic treatment, prolactin, and breast tumorigenesis. [Journal Article]
  • Psychiatr Danub 2016; 28(3):243-254PD
  • De Hert M, Vancampfort D, … Detraux J
  • CONCLUSIONS: The role of PRL in breast carcinogenesis therefore remains unclear, unconfirmed, yet controversial. Antipsychotics should not be withhold for breast cancer prevention reasons to patients in need of this sometimes life-saving medication, even if classical breast cancer risk factors are present.
  • Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. [Journal Article]
  • Clin Endocrinol (Oxf) 2016 Sep 21CE
  • Watanabe S, Akutsu H, … Matsumura A
  • CONCLUSIONS: Cabergoline therapy can achieve a high percentage (73% in this series) of remission maintenance for at least 12 months after cessation of a 5-year course of therapy, even in patients with macroprolactinomas. Absence of cavernous sinus invasion, serum PRL level lower than 132.7 ng/ml before cabergoline therapy, or nadir serum PRL below 1.9 ng/ml were related to more frequent remission after withdrawal of cabergoline in patients receiving this medication for 5 years. This article is protected by copyright. All rights reserved.
  • Long-term outcome of macroprolactinomas. [Journal Article]
  • Ann Endocrinol (Paris) 2016 Sep 15AE
  • Képénékian L, Cebula H, … Goichot B
  • CONCLUSIONS: Macroprolactinoma is currently most often a chronic disease controlled with DA. However, uncertainty about the adverse effects associated with high cumulative doses and the lack of data on the prognosis at very long-term should incite to revisit current strategies, including the role of surgery combined to medical treatment.
  • [Prolactin, antipsychotics and breast cancer: is there a connection?]. [Journal Article]
  • Tijdschr Psychiatr 2016; 58(9):641-9TP
  • Sabbe T, Detraux J, De Hert M
  • CONCLUSIONS: There is no conclusive evidence that antipsychotic medication that raises prolactin levels increases the risk of breast cancer. Nevertheless, clinicians should always be cautious about prescribing antipsychotics for breast cancer patients. In our view, clinicians should always treat breast cancer risk factors as efficiently as possible, particularly when attending to patients who have schizophrenia.
New Search Next